6 MAJOR ASCO UPDATE HIGHLIGHTS
OVERALL SURVIVAL DATE of PALBOCICLIB presented (TRIO-18) in first line setting.
Benefit of wonder drug DACOMITINIB over GEFATINIB in treatment of advance EGFR positive non small cell lung cancer.
Positive outcome of phase 3 data of trastuzamab with palbociclib.
First line usage of pfizer and e.merck immuno oncology product avelumab plus axitinib.
Successful phase 3 trial results of SUTENT in adjuvent setting.
Efficacy and safety of lorlatinib in ALK positive lung cancer over Crizotinib ceritinib and alectinib.